Eli Lilly and Company, a global pharmaceutical giant, has recently seen frequent new appointments in its senior management.
Appointment of the First Chief Artificial Intelligence Officer, Ushering in a New Era of AI Healthcare
October 10, Eli Lilly and CompanyAnnouncement of the Appointment of Thomas J. Fuchs as the Company's First Chief Artificial Intelligence Officer, effective from October 21, 2024.This decision not only marks Eli Lilly's deep investment in the field of artificial intelligence but also may foreshadow a more intelligent future for the healthcare industry.Thomas J. Fuchs has an extensive background in the fields of artificial intelligence and healthcare. Prior to joining Eli Lilly and Company, he served as the Dean and Inaugural Chair of the School of Artificial Intelligence and Human Health at Mount Sinai, Director of the Hasso Plattner Institute for Digital Health at Mount Sinai, and Professor of Artificial Intelligence and Computational Pathology at the Icahn School of Medicine at Mount Sinai, making significant contributions to advancing research on the integration of AI in healthcare.Under his leadership, Eli Lilly will launch a series of AI-related projects, covering multiple areas such as drug discovery and clinical trials. This transformation, which transcends the traditional pharmaceutical model, is of great significance for improving R&D efficiency and shortening time to market, ultimately better serving patients and enhancing the quality of healthcare.Eli Lilly China Management Team: Yan Qiong Newly Appointed as Vice President of the Diabetes Products Division
On October 9, Huzur Devletsah, President and General Manager of Eli Lilly China, announced a significant management appointment to the employees.Effective October 10, Yan Qiong assumed the role of Vice President of the Diabetes Products Division, becoming a member of the Lilly China management team., directly reporting to Huzur Devletsah.This appointment marks a key step for Eli Lilly China in a new phase of business development.
Yan Qiong's career is quite extensive, and she has worked atNovartis serves as the Senior Vice President in the field of oncology treatment, with extensive industry experience.After joining Eli Lilly, she will take on the responsibility of promoting Eli Lilly's blockbuster products.The重任 of Tirzepatide and its metabolic product series in the Chinese market growth.This appointment not only reflects Eli Lilly's emphasis on the Chinese market but also highlights the company’s ambitious goals in the field of diabetes treatment. The addition of Yan Qiong will undoubtedly bring new vitality and strategic perspective to Eli Lilly China, helping the company stand out in a highly competitive market environment.
Statement:All articles published on this official account (including original and reprinted articles) are intended to convey more information, and the sources and authors are credited. This official account welcomes sharing in friend circles or large groups.Reproduction in any form by media or organizations without authorization is prohibited.。Reprint/Business/Contribution| Contact WeChat15618157102（sum_Gmi）
